ClinicalTrials.gg
CompletedNCT03445208Updated Mar 19, 2020

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

A Phase 1 interventional study of BMS-986036 in Hepatic Cirrhosis, Liver Fibrosis and Nonalcoholic Fatty Liver Disease, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-19.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2018, 8 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 231 studies in Liver Cirrhosis with a site in United States — 45 open to participants now, 63 under way, 3 of them phase 3. Liver Cirrhosis · United States.

Enrollment
108th of 166
30 · median 55
Started
2018
with 20 others
Phase 1
26 of 231
4 open now
Registered
89th of 231
by date
Lead sponsor
5 of 231
Bristol-Myers Squibb

Among the 231 studies in Liver Cirrhosis with a site in United States, this one is the 108th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2018, is one of 26 in phase 1, and was the 89th registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

45 of the 231 studies in Liver Cirrhosis with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Liver Cirrhosis with a site in United States, or all of them as a file.
02

Study summary

This is a study of experimental medication BMS-986036 given to healthy participants.

03

Conditions studied

  • Hepatic Cirrhosis
  • Liver Fibrosis
  • Nonalcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy participant, as determined by no deviations from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
  • of 18 to ≤ 40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Presence of any factors that would predispose the participant to infection (eg, extensive periodontal disease that warrants surgical or medical treatment, unhealed open wounds)
  • Any bone trauma (fracture) or bone surgery (i.e. hardware placement, joint replacement, bone grafting, or amputation) within 3 months of study drug administration
  • Known or suspected disorder, excluding vitiligo
  • Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease
  • Any major surgery within 6 weeks of study drug administration
  • History of diabetes mellitus

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    BMI 18.0 to ≤ 25.0

    Drug: BMS-986036

  • Experimental
    Cohort 2

    BMI \>25.0 to ≤ 30.0

    Drug: BMS-986036

  • Experimental
    Cohort 3

    BMI \>30.0 ≤ 40.0

    Drug: BMS-986036

Interventions

  • Crossover administration to abdomen then upper arm

06

What researchers measure

Primary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: 29 days

  2. Time of maximum observed serum concentration (Tmax)

    Time frame: 29 days

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)]

    Time frame: 29 days

  4. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(0-inf)]

    Time frame: 29 days

Secondary outcomes

  1. Number of injection site reactions

    Time frame: Up to 78 days

  2. Number of adverse events (AE)

    Time frame: Up to 78 days

  3. Number of serious adverse events (SAE)

    Time frame: Up to 78 days

  4. Number of AEs leading to discontinuation

    Time frame: Up to 78 days

  5. Number of deaths

    Time frame: Up to 78 days

  6. Serum biomarker antibody concentration

    Time frame: Up to 78 days

07

Study locations

1 site
  • PRA Health Sciences
    Salt Lake City, Utah 84107, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2018, 2 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Feb 26, 2018
StartActual
Feb 14, 2018
Primary completionActual
May 2, 2018
CompletionActual
May 2, 2018
Last update
Mar 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03445208
Responsible party
Sponsor
First posted
Feb 26, 2018
Start date
Feb 14, 2018
Primary completion
May 2, 2018
Completion
May 2, 2018
Last update
Mar 19, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegbelfermin

Start the discussion